In the context of this review, AR-targeted biased ligands can allow for fine-tuning therapeutic approaches for IHD, ischemia-reperfusion injury, heart failure, and myocardial infarction [129,130,131,132,133]. This evidence concerns the gene AR and myocardial ischemia.